Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 10/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787244 | 0.84 | TDP1 (0.41) | TDP1DRD4DRD2MAPTHTT | |
| SCHEMBL2770616 | 0.84 | TDP1 (0.46) | TDP1DRD4DRD2MAPTHTT | |
| SCHEMBL8434495 | 0.75 | SLC6A2 (0.40) | TDP1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL2771673 | 0.72 | TDP1 (0.56) | TDP1DRD4DRD2MAPTHTT | |
| SCHEMBL1303034 | 0.65 | POLB (0.50) | MAPTHTTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18574082 | 0.64 | CYP1A2 (0.56) | DRD4DRD2MEN1KMT2AALDH1A1 | |
| SCHEMBL391910 | 0.64 | CYP1A2 (0.56) | DRD4DRD2MEN1KMT2AALDH1A1 | |
| SCHEMBL7871655 | 0.64 | GSK3B (0.73) | DRD4DRD2NPSR1SLC6A4MEN1 | |
| SCHEMBL8429960 | 0.63 | SLC6A2 (0.40) | TDP1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL2645826 | 0.63 | L3MBTL1 (0.56) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643989-B1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-7132421-B2 | CIS-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1643989-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005002575-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040259867-A1 | CIS-imidazoles | FOTOUHI NADER (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040259867-A1 | CIS-imidazoles | FOTOUHI NADER (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259867-A1 | CIS-imidazoles | TP53, MDM2, TP53BP1 | TDP1 1038/4885DRD4 4388/4885DRD2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.